|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:liraglutide
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:affiliatedWith
|
GLP-1 receptor agonist
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:associatedWith
|
gptkb:Victoza
|
|
gptkbp:ATCCode
|
A10BJ02
|
|
gptkbp:brand
|
gptkb:liraglutide
|
|
gptkbp:chemicalFormula
|
C172H265N43O51
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
13 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Saxenda
|
|
gptkbp:indication
|
obesity
overweight with comorbidities
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:molecularWeight
|
3751.2 g/mol
|
|
gptkbp:notRecommendedFor
|
gptkb:type_2_diabetes
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
nausea
vomiting
diarrhea
constipation
pancreatitis
|
|
gptkbp:usedFor
|
weight management
|
|
gptkbp:bfsParent
|
gptkb:liraglutide
gptkb:GLP-1_agonists
|
|
gptkbp:bfsLayer
|
7
|